⌘K
Loading ticker…
Immunovant, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Immunovant, Inc. Common Stock (IMVT) has a 3-month relative strength percentile of 90 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 77. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.6%, relative volume 2.19×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 90, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
IMVT is in a stage 2 uptrend, week 6. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 24.6% / 53.8%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
IMVT is held by 8 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $65M notional. Top 3 carry $177M.
Top 8 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $65M |
| XBIState Street SPDR S&P Biotech ETF | 0.86% | $64M |
| IWMiShares Russell 2000 ETF | 0.07% | $49M |
| VBVanguard Small Cap ETF | 0.03% | $47M |
| VBKVanguard Small-Cap Growth ETF | 0.07% | $26M |
| VXFVanguard Extended Market ETF | 0.03% | $21M |
| IWOiShares Russell 2000 Growth ETF | 0.14% | $17M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $3M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IMVT Jan avg: -5.85% median: -6.06% win: 50% σ: 8.21% n: 4 2022-04-12 → 2026-05-29 | IMVT Feb avg: -0.78% median: -2.27% win: 25% σ: 5.17% n: 4 2022-04-12 → 2026-05-29 | IMVT Mar avg: -11.83% median: -10.82% win: 0% σ: 3.63% n: 4 2022-04-12 → 2026-05-29 | IMVT Apr avg: -2.82% median: -5.50% win: 40% σ: 9.59% n: 5 2022-04-12 → 2026-05-29 | IMVT May avg: 5.86% median: -7.47% win: 40% σ: 18.96% n: 5 2022-04-12 → 2026-05-29 | IMVT Jun avg: -1.50% median: -2.02% win: 50% σ: 8.67% n: 4 2022-04-12 → 2026-05-29 (current) | IMVT Jul avg: 9.15% median: 7.88% win: 100% σ: 8.43% n: 4 2022-04-12 → 2026-05-29 | IMVT Aug avg: 5.53% median: 2.89% win: 50% σ: 14.34% n: 4 2022-04-12 → 2026-05-29 | IMVT Sep avg: 19.85% median: 9.04% win: 75% σ: 33.74% n: 4 2022-04-12 → 2026-05-29 | IMVT Oct avg: 35.63% median: 27.87% win: 75% σ: 51.91% n: 4 2022-04-12 → 2026-05-29 | IMVT Nov avg: 7.42% median: 7.45% win: 50% σ: 11.93% n: 4 2022-04-12 → 2026-05-29 | IMVT Dec avg: 9.04% median: 6.46% win: 75% σ: 19.67% n: 4 2022-04-12 → 2026-05-29 |